For U.S. Healthcare Professionals Only

Visit Sanofi U.S.:


Definitive diagnosis is established by:


  • α-galactosidase A enzyme assay is diagnostic—measures enzyme level in plasma and leukocytes1
  • Affected males have reduced α-galactosidase A activity in plasma and leukocytes1 compared to normal reference ranges


  • Enzyme assay alone is frequently insufficient for diagnosis in females2
  • DNA-based diagnosis is required/gold-standard for females with normal to low-normal enzyme activity levels and is advisable in all suspected patients2

  • The addition of biomarker lyso-GL3 may increase the sensitivity of diagnostic testing in females


References: 1. Ortiz A, et al. Mol Genet Metab. 2018;123:416-427. 2. Smid BE, et al. J Med Genet. 2015;52:262–268.




Last Updated: Feb 6, 2021
What's New

What's New

New to molecular testing?
This 4 minute video illustrates the path a healthcare provider takes when ordering diagnostic testing for a lysosomal storage disease for the first time, and offers tips along the way.



Contact the Rare Diseases Medical Affairs team

Event Calendar

Event Calendar

Find Upcoming Events and Presentations on Our Event Calendar